Clinical Trial Update: Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] [Phase 2]

View source ↗

Summary

Phase 2 trial of nintedanib alone or with capecitabine in refractory metastatic colorectal cancer (LUME-Colon 2) has been terminated with results posted in 2018…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2018-10-11